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Abstract: Cardiovascular disease is a major cause of death globally. This has led to significant efforts
to develop new anti-thrombotic therapies or re-purpose existing drugs to treat cardiovascular diseases.
Due to difficulties of obtaining healthy human blood vessel tissues to recreate in vivo conditions,
pre-clinical testing of these drugs currently requires significant use of animal experimentation,
however, the successful translation of drugs from animal tests to use in humans is poor. Developing
humanised drug test models that better replicate the human vasculature will help to develop anti-
thrombotic therapies more rapidly. Tissue-engineered human blood vessel (TEBV) models were
fabricated with biomimetic matrix and cellular components. The pro- and anti-aggregatory properties
of both intact and FeCl3-injured TEBVs were assessed under physiological flow conditions using
a modified parallel-plate flow chamber. These were perfused with fluorescently labelled human
platelets and endothelial progenitor cells (EPCs), and their responses were monitored in real-time
using fluorescent imaging. An endothelium-free TEBV exhibited the capacity to trigger platelet
activation and aggregation in a shear stress-dependent manner, similar to the responses observed
in vivo. Ketamine is commonly used as an anaesthetic in current in vivo models, but this drug
significantly inhibited platelet aggregation on the injured TEBV. Atorvastatin was also shown to
enhance EPC attachment on the injured TEBV. The TEBV, when perfused with human blood or blood
components under physiological conditions, provides a powerful alternative to current in vivo drug
testing models to assess their effects on thrombus formation and EPC recruitment.
Keywords: cardiovascular disease; ketamine; atorvastatin; platelets; endothelial progenitor cells;
test tissue models
1. Introduction
Cardiovascular diseases are among the leading causes of mortality and morbid-
ity worldwide. These are caused by aberrant platelet activation caused by endothelial
dysfunction and exposure of plasma to collagen- and tissue factor-rich atherosclerotic
plaques. However, it is not possible to study this practically or ethically in human patients.
Most studies assessing the effect of drugs on cardiovascular disease rely on animal models
to predict and explain their effects in humans [1]. Different animal species have been
used to evaluate certain features of cardiovascular disease, such as zebrafish, pigs, rabbits,
and rodents. Mice have become the animal of choice for disease modelling given their
genetic similarity to humans, their fast breeding rate, and well-established methods for
creating genetic knock-outs [2,3]. Additionally, intravital microscopy allows the real-time
examination of thrombus formation on artificial vessel injuries in response to ferric chloride
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(FeCl3) or laser injury [4]. These arterial thrombosis models have become popular for
examining the molecular mechanisms underlying thrombus formation and how these can
be impacted by drug treatments.
The interpretation of the data obtained from murine thrombosis models is complicated
by the use of anaesthetics. A survey of investigators performing intravital microscopy
in murine thrombosis models found that ketamine, xylazine, and pentobarbital are the
most commonly used anaesthetics [5]. However, previous studies have demonstrated that
each of these anaesthetics can have an inhibitory effect on platelet function [5–7]. For in-
stance, ketamine inhibited platelet aggregation through the suppression of IP3 formation
and also by inhibiting thromboxane synthase activity [7,8]. Additionally, ketamine can
also interfere with endothelial nitric oxide production, as well as smooth muscle Ca2+
signalling [9,10]. This suggests that the use of ketamine in intravital microscopy studies
could create a baseline inhibition of platelet function as well as modulation of normal
haemostatic properties of the vessel wall, which could overestimate the effect of genetic
knockouts or drug treatments on normal haemostatic responses.
These shortcomings provide an opportunity to create alternative thrombosis models
by recreating normal haemostatic conditions by flowing human blood through human
tissue-engineered arterial constructs. Tissue-engineered arteries were initially produced
to use as alternatives to autologous vessels for vascular grafting. Vascular tissue en-
gineering was pioneered in 1986 by Weinberg and Bell, who generated the first tissue-
engineered blood vessels (TEBVs) by culturing vascular cells on a collagen-based scaf-
fold [11]. Nearly 40 years later, there are few TEBVs currently being used in clinical
application. However, great progress has been made in improving the biomimicry of
TEBVs. A number of previous studies have demonstrated that it is possible to gener-
ate tissue-engineered arteries through a variety of methods that can withstand normal
arterial blood flow conditions whilst replicating the functional properties of the native arter-
ies [12–14]. This has been achieved through using a variety of approaches including the use
of a variety of scaffold material both synthetic (e.g., polyvinyl alcohol and gelatin [15]) and
natural extracellular matrix molecules (collagen, elastin [16]). The properties of these scaf-
folds can be further modified to increase their mechanical strength through compression or
chemical crosslinking or made more porous by freeze-drying [16]. Furthermore, the use
of bioreactors has been influential in producing ideal culture conditions for vascular cells
to ensure they assume the cellular phenotypes found in vivo [17]. These approaches have
created TEBVs that possess a number of desirable properties such as the ability to support
physiological spiral laminar flow [15], to mechanically withstand physiological arterial
blood pressures [15,16], and to support the growth of a healthy endothelial cell lining [17].
This is consistent with the key parameters required for a substrate for clinical vascular
grafting. These studies have commonly assessed the ability of the TEBVs to withstand
activation of haemostatic and inflammatory responses of blood cells flowing through them.
However, to utilise TEBVs as an animal-free alternative to current in vivo arterial thrombo-
sis models requires a demonstration that they are capable of eliciting appropriate cellular
reactions upon damage and that drug treatments are able to modulate that response.
Previously, we have utilised tissue engineering approaches to create human arterial
models that replicate the normal haemostatic properties of the intimal and medial lining of
human arteries [18]. This includes the use of an electrospun polylactic acid (PLA) nanofiber
scaffold to create an intimal layer construct that provides contact guidance to ensure that
the endothelial cells can be aligned in the direction of flow, similar to the native artery.
The medial layer construct is formed by human coronary artery smooth muscle cells cul-
tured within a collagen hydrogel. Musa et al. (2016) showed that their tissue-engineered
blood vessels are able to replicate the anti- and pro-aggregatory properties of native arteries
when the intimal layer is intact and absent, respectively [18]. Our real-time spectrofluo-
rimetry measurements of cytosolic Ca2+ signalling provided a sensitive method to assess
platelet activation upon exposure to the tissue-engineered constructs. These results clearly
demonstrate that the intimal, medial, and full blood vessel constructs replicate the in vivo
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ability to modulate platelet function [18]. The thrombus formation upon the surface of the
construct indicated by aggregated DiOC6-labelled platelets under a fluorescent microscope
can be visualized in the consequent examination. However, these studies were performed
under non-physiological mixing conditions. We have not previously examined the ability
of the constructs to support thrombus formation under physiologically relevant shear stress
from perfusion of platelets. The flexibility of a layer-by-layer fabrication approach in tissue
engineering in conjunction with a perfusion device offers a great opportunity to study
endothelial dysfunction and repair mechanisms. Endothelial function is an important and
independent predictor for the severity of cardiovascular disease. An impaired endothelium
is a key driver in the development of cardiovascular disease [19]. Circulating bone marrow-
derived endothelial progenitor cells (EPCs) have been found to correlate to endothelial
function and to aid in neovascularisation and re-endothelialisation of injured vessels, main-
taining vascular function and homoeostasis [19,20]. In models of myocardial infarctions
and arterial injury, EPCs have been shown to localize preferentially to sites of vascular
lesions, after which they divide, proliferate, and become incorporated into the endothelial
layer of existing vessels, and promote the outgrowth of new vascular networks. These cells
also have an effect on surrounding cells by producing angiogenic growth factors [21,22].
The most common drugs used to treat/prevent the development of cardiovascular
disease are statins, with atorvastatin being the most well-known. This drug has been in use
for decades, and its effects have been extensively studied. Some of these include reduction
of the accumulation of esterified cholesterol into macrophages, increase of endothelial
nitric oxide (NO) synthase, reduction of the inflammatory process, increased stability of
the atherosclerotic plaques, and restoration of platelets activity and of the coagulation
process [23,24]. Despite the known pleiotropic actions of atorvastatin, there is currently
limited data on the impact this drug has on EPC ability to mediate endothelium repair.
In this study, we aimed to examine whether our tissue-engineered (TE) human arterial
models were able to mimic the pro- and anti-aggregatory properties of the damaged and
intact artery under physiological flow conditions. We also aimed to examine whether
our tissue-engineered arterial constructs could support EPC recruitment and whether
this could be modulated by drug treatments. This was achieved by incorporating the
constructs within a commercially available parallel-plate flow chamber and perfusing
them with washed human platelet suspensions at arterial shear stresses. We examined
whether this biomimetic test model system could be used as a potential alternative to
in vivo drug testing models in thrombosis and EPC homing. This system was used to
perfuse platelets and various cell populations over the TE constructs at physiologically
relevant or pathological shear stress, allowing the real-time profiling of their interactions,
and for the evaluation of changes in both the surface and structure of the blood vessel,
as well as changes in the perfusate. The impact of ketamine on platelet activation and
the effect of atorvastatin on EPC homing when EPC being exposed to TEBVs with a
FeCl3-induced lesion were investigated. Through these studies, we demonstrated that
human tissue-engineered arterial constructs, when perfused with human blood or freshly
prepared washed human platelet suspension under physiological conditions, provide a
human model system that can be used to study the effect of drugs without the potential
confounding impact of species differences and use of anaesthetics.
2. Materials and Methods
2.1. Fabrication of 3D Tissue-Engineered Blood Vessel Constructs
Fabrication of 3D tissue-engineered intimal layers (TEILs), media layers (TEMLs), and
the complete tissue-engineered blood vessel was achieved using human umbilical vein
endothelial cells (HUVECs) and human cardiac artery smooth muscle cells (HCASMCs),
both obtained from GIBCO, Life Technologies. Cells were cultured with medium 200 and
231, respectively, also obtained from GIBCO, Life Technologies, and used between passage
numbers 2 and 5. The construction of the TEIL, TEML, and TEBV constructs was performed
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using our previously described methodology [18], as such these protocols are outlined
briefly below.
2.2. Electrospinning
Aligned nanofibers were made by dissolving Poly-L,D-lactic acid (96% L/4% D, inher-
ent viscosity of 5.21 dL/g, Purac BV, Gorinchem, the Netherlands) (PLA) in a 7:3 mixture
of chloroform and dimethylformamide (DMF) (Sigma, Welwyn Garden City, UK) into 2%
solution. The operational parameters of nanofiber fabrication followed the established
protocol [25]. In brief, this 2% PLA solution was deposited onto detachable metal collectors,
comprised of two partially insulated steel blades (30 cm × 10 cm), and connected to a
permanent copper plate with a steel wire. The two steel blades had a gap of 5 cm between
them where the fibers were deposited. Deposition of the fibers involved connecting the
permanent plate to a negative electrode, and a syringe containing the solution was con-
nected to a positive electrode. The PLA was extruded through an 18G needle and delivered
at a rate of 0.025 mL/min. The electrodes were electrified with a power supply charged
at ±6 kV (Spellman HV, Pulborough, UK). Nanofibers were collected and affixed onto
acetate frames and were sterilized by UV irradiation thrice per side before use in culture.
The nanofiber diameter was measured as ~500 µm and the mat thickness ~3 µm [25].
The porosity of the mat was smaller than 1 µm since no endothelial cells were observed to
migrate through the nanofiber layer [18].
2.3. TEML Assembly
To create TEML constructs, HCASMCs, at a density of 5 × 105 cells /mL, were mixed
with neutralized 3 mg/mL type I collagen (Corning) solution. Two hundred microlitres of
this solution was loaded onto 0.5 cm × 2.0 cm filter paper frames, which fit the dimensions
of the parallel-plate flow chamber. The formed TEML constructs were used when the
HCASMCs attained typical spindle-shaped morphology and reached confluence. TEMLs
were cultured in whole medium 231, with media changes every 2 days for up to 10 days.
2.4. TEIL Assembly
To prepare TEIL constructs, a neutralized acellular collagen gel (3 mg/mL), having
the same dimensions detailed above, was formed first. Once the gel set, aligned PLA
nanofibers [18], coated in 10 ng/mL fibronectin, were placed on the surface of the gel.
HUVECs were then seeded at a density of 2 × 105 cells/mL on the nanofibers. The TEIL
samples were cultured in whole medium 200, with media changes every 2 days, for 10 days
to allow attainment of normal cell morphology and surface area coverage.
2.5. TEBV Assembly
This model was a combination of the TEIL and TEML. TEML was created first and
HUVECs seeded, as previously described, on fibronectin-coated PLA nanofibers after
HCASMCs attained desired spindle-shaped morphology. The complete TEBV was returned
to culture with HCASMC and HUVEC whole media mixed 7:3. The schematic for TEML,
TEIL, and TEBV assembly is shown in Figure 1.
Figure 1. Schematic representation of a 3D human tissue-engineered blood vessel (TEBV). The di-
agram shows the structure of the tissue-engineered (TE) construct and the locations of the cells
within the intimal (TEIL) and medial layer (TEML). The medial layer adopts an eventual thickness of
approximately 3 mm while the intimal layer atop the nanofibers is approximately 30 µm.
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2.6. Perfusion System
2.6.1. Perfusion Chamber
To generate peristaltic flow and a range of shear stress values, a peristaltic pump
(Watson-Marlow 505 series, Watson-Marlow Fluid Technology, Falmouth, UK) was used
along with a commercially sourced parallel-plate flow chamber (ProFlow chamber; Warner
Instruments, Hamden, CT, USA) modified as outlined below. Media to be perfused was
contained in a 7 mL reservoir connected to the pump and flow chamber using polyethylene
(PE-90) tubing as shown in Figure 2.
Figure 2. Schematic drawing and image illustrating the perfusion chamber assembly. The sample is
aligned along the flow path between the inlet and outlet on the bottom plate. The outlet, affixed with
silicone grease to the top plate, is aligned in the same way and placed over the sample. The assembled
chamber is connected to a reservoir and a peristaltic flow pump.
2.6.2. Perfusion Gaskets
To facilitate the perfusion of our 3D vascular models, a specialized gasket was created.
The gasket was manufactured using polydimethylsiloxane (PDMS). A circular ring with a
diameter of 30 mm was first cut, then a 25 mm (length) × 5 mm (width) × 3 mm (depth)
rectangular opening in the centre of the circle (Figure 2).
2.6.3. Parallel-Plate Flow Chamber and Shear Stress
The assembled flow chamber was used to generate laminar flow to exert physiological
shear stress on the intimal surface of the TEBV. The dimensions of the gasket used comprise
and determine the dimensions of the flow chamber. The equation used to determine the




where u is the viscosity of the fluid being perfused (1.5 Cp), Q being the flow rate (Q; either
0.077 cm3/s and 0.007 cm3/s), b the width of the gasket opening (5 mm), and h being the
height between the upper surface of the construct and top plate of the chamber (2.5 mm).
The two fluid-flow rates used provided shear stresses of 22.2 dyne/cm2 and 2.2 dyne/cm2
for the performed experiments which are consistent with arterial and venous shear rates
respectively [26,27].
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2.7. Lesion Models
To mimic vascular injury, a FeCl3 lesion was created on the TEBV by dipping a 1 mm2
square of filter paper in 10% FeCl3 and placing this onto the upper surface of the TE
constructs for 1 min. After this, the TE constructs were washed with PBS/HBS to eliminate
excess FeCl3, then topped up with fresh media. This mode of lesioning was also applied to
TE constructs for EPC perfusion.
2.8. Platelet Preparation
This study was approved by the Keele University (UK) Research Ethics Committee
(MH-200155, 1 May 2018). Blood was donated by healthy, drug-free volunteers who
gave written informed consent. Blood was obtained by venepuncture. The blood was
mixed with acid citrate dextrose (ACD; 85 mM sodium citrate, 78 mM citric acid, and
111 mM D-glucose) at a ratio of 5:1. Platelet-rich plasma (PRP) was obtained by soft
descent centrifugation at 725 g for 8 min. After centrifugation, the PRP was collected
and treated with aspirin (50 mM) and apyrase (0.1 U/mL). PRP was again centrifuged at
450 g for 20 min, then resuspended in supplemented HEPES-buffered saline (HBS; pH 7.4,
145 mM NaOH, 10 mM HEPES, 10 mM D-glucose, 5 mM KCl, 1 mM MgSO4) to reach a
platelet density of 2 × 108 cells/mL. The HBS was supplemented with 1 mg/mL bovine
serum albumin (BSA), 1.8 mg/mL glucose, 0.1 U/mL apyrase, and 200 µM CaCl2. Prior to
perfusion, the assembled perfusion system without the TE construct was perfused with
1% BSA solution for 1 h to prevent unwanted platelet adhesion to the components of the
perfusion system. The gasket and the spacers were incubated overnight with 1% BSA
solution at room temperature.
2.9. EPC Isolation and Culture
EPCs were isolated by collecting 60 mL of whole blood from healthy volunteers.
To prevent coagulation, the blood was split into 2 falcon tubes with 5 mL of ACD in each.
The blood-anticoagulant mix was then split into 15 mL falcon tubes and centrifuged at 700 g
for 8 min. After centrifugation, the sequence of layers occurred as follows (seen from top to
bottom): plasma, enriched cell fraction (interphase consisting of lymphocytes/peripheral
bone marrow cells (PBMCs), erythrocytes, and granulocytes. The plasma fraction was
carefully discarded, leaving approximately 0.5–1 mL above the interface. The enriched cell
fraction was pooled into one tube and diluted 1:1 with PBS. To further separate the cell, i.e.,
eliminate residual plasma and Red Blood Cells (RBCs), the pooled fraction was carefully
layered over 8 mL of Ficoll-Paque, ensuring no mixing of the layers, and centrifuged
again for 20 min at 400 g. After centrifugation, any residual red blood cells are below the
separation medium, and the enriched cell fraction should be immediately above it with
diluted plasma and platelets above this. After isolation, the cell-rich fraction was diluted
with PBS, then centrifuged again at 400 g for 10 min. After centrifugation, the supernatant
was discarded, and the resultant pellet was resuspended in 2 mL of complete EPC media.
The cell suspension was then split into 2 wells of a 12-well plate that had been coated with
2.5 µg/cm2 fibronectin. On day 1, the contents of the wells were agitated and transferred
to new wells. This was repeated for the next 3 days. Media was changed daily for the first
7 days then every 2–3 days for up to 20 days.
2.10. Cell Labelling
2.10.1. CFSE
Carboxyfluorescein succinimidyl ester (CFSE) dye was used to label EPC cells at a
concentration of 2 µL/mL of cell suspension. Cells were incubated for 15 min at 37 ◦C,
then centrifuged for 3 min at 300 g. The pellet was re-suspended in 5 mL of fresh supple-
mented media. The cell suspension was allowed to rest for 30 min at 37 ◦C before loading
into the perfusion system.
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2.10.2. DiOC6
To facilitate visualization of platelet adhesion and aggregation upon the TE constructs
under flow conditions, platelets were labelled with DiOC6, a fluorescent membrane dye.
Blood was mixed 5:1 with ACD (anticoagulant). The anticoagulant was mixed with the
membrane dye to make a final concentration of 1µM, prior to the addition of whole blood.
This mixture was then incubated for 10 min at room temperature, then centrifuged to
obtain PRP. Centrifugation was done at 1500 g for 8 min. The resultant PRP was then
treated with 100 µM aspirin and 0.1 U/mL apyrase. This was followed by a centrifugation
wash at 350 g for 20 min. The platelet pellet was then re-suspended with supplemented
HBS, creating a final cell density of 2 × 108 cells/mL.
2.11. Ketamine Treatment
To assess if the platelet responses might be affected by ketamine treatment, exper-
iments were performed in which both platelets and the TE constructs were pre-treated
with ketamine before the perfusion of platelets on TE constructs. TEMLs were incubated
with 1 mM ketamine (Narketan) or HBS for 1 h at 37 ◦C, after which they were perfused
with washed DiOC6-labelled platelets incubated with either 300 µM ketamine or an equiv-
alent volume of the vehicle, or HBS, under the same conditions stated above. Platelet
aggregation on the perfused TE constructs was evaluated by fluorescence microscopy
(Leica MSV269) under excitation wavelength of 485 nm and emission of 501 nm. As a
static comparative, TE constructs were treated with 1 mM ketamine and placed in a cuvette
with DiOC6-labelled platelets treated with ketamine or HBS for 15 min at 37 ◦C. Whilst
untreated TEML constructs were placed atop untreated platelet samples as the control.
2.12. Platelet Aggregometry
Platelet aggregometry was performed using a modification of the previously published
technique [28]. Following platelet incubation with TE constructs, 200 µL of the platelet
suspension was transferred into a 96-well plate and then placed into a plate reader pre-
warmed to 37 ◦C (BioTek Synergy 2 microplate, Winooski, VT, USA). Baseline absorbance
readings were taken once at a wavelength of 600 nm, obtaining an absolute absorbance
reading post TE construct incubation. In the present assay, the plate reader was set up to
use a fast-shaking mode between absorbance readings to aid in sample mixing.
2.13. Atorvastatin Treatment
Following FeCl3 lesioning, the TE constructs were incubated with 60 µg/mL ator-
vastatin calcium trihydrate (Sanofi) for 3 and 5 h at 37 ◦C. This was followed by the
perfusion of CFSE-labelled EPCs (without atorvastatin in EPC perfusate as control) for
45 min in the parallel-plate chamber. Images were taken using a Leica inverted microscope
(Leica MSV269) under an excitation wavelength of 485 nm and emission of 501 nm. Cell
attachment was quantified with ImageJ.
2.14. Statistics and Data Analysis
Values stated are mean ± SEM of the number of observations (n) indicated. Analysis
of statistical significance was performed using a two-tailed Student’s t-test as well as two-
way analysis of variance (ANOVA), confirmed using the Brown–Forsythe test. p < 0.05 was
considered statistically significant.
3. Results
The adhesion and aggregation of platelets by exposure to the TE constructs under
dynamic flow conditions were assessed by monitoring fluorescence from DiOC6-labelled
human platelets upon the surface of the TE constructs (solid phase activation), as well as
monitoring activation of platelets remaining within the solution by platelet aggregome-
try (liquid phase activation). Three types of TE constructs were evaluated, TEIL, TEML,
and TEBV, with the acellular collagen hydrogel as a negative control as we have previ-
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ously demonstrated this to not elicit platelet activation [18]. The homing effect of drug
atorvastatin on EPC attachment on these TE constructs under dynamic flow conditions
was assessed.
3.1. Cells in TE Constructs Attained Typical Morphology and Organisation
Consistent with our previous findings, it was possible to generate TEIL, TEML, and
TEBV constructs with HUVECs and HCASMCs showing typical normal cellular morphol-
ogy when grown atop (HUVECs) or within (HCASMCs) the collagen hydrogel scaffold
using our previously published layer-by-layer fabrication technique [18]. Figure 3 demon-
strates the effect of aligned nanofibers on HUVEC alignment, with cells showing more
organised growth/orientation compared to culture flasks. Meanwhile, smooth muscle
cells maintain spindle-shaped morphology while embedded in the collagen gel (data not
shown [18]).
Figure 3. Cellular morphology for TEIL constructs. (A) Human umbilical vein endothelial cells (HUVECs) cultured for
4 days in a culture flask. (B) HUVECs cultured on the nanofibers for 10 days, (C) SEM picture of aligned PLA nanofibers.
3.2. TEML Supports Shear-Dependent Platelet Aggregation under Physiological Flow Conditions
We first assessed whether the TEML is able to support platelet aggregation under
two different shear stresses indicative of those found in the arterial (22.2 dyne/cm2) and
in the venous circulation (2.2 dynes/cm2; [29]). The TEML construct is a model for an
endothelium-denuded blood vessel and therefore can be used to assess pro-aggregatory
properties of the medial layer. Figure 4A,B show that acellular collagen gels did not trigger
platelets’ activation under both low and high shear stress rate, consistent with our previous
findings under static conditions [18]. When the TEML constructs were exposed to platelets
perfused at venous shear stresses, sporadic platelet adhesion was observed (Figure 4C).
The strong platelet aggregation observed under arterial shear stresses demonstrates that
shear stress and fluid flow influence platelet adhesion (Figure 4D). These studies are
consistent with a number of previous studies that have demonstrated a role for shear-
dependent platelet aggregation in driving thrombus formation [30,31].
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Figure 4. Fluorescence images of tissue-engineered media layer (TEML) constructs after exposure to
platelets perfusion at different shear stress rates. DiOC6-labelled human platelets suspension was
perfused through a parallel-plate flow chamber over the surface of acellular collagen gels (A,B) and
TEML (C,D) for 15 min at venous (A,C) (2.2 dyne/cm2) and arterial (B,D) (22.2 dyne/cm2) shear
stresses. White dotted line denotes the central hydrogel area. Area on either side of the dotted line is
the filter paper frame. Arrows highlight aggregated platelets.
The platelets adhered and significantly aggregated when exposing to the media layer
of the constructs (Figure 4D). Since no aggregation was observed on the acellular hydrogels
(Figure 4A,B), platelet aggregation should be triggered by neo-collagen produced by the
embedded HCASMCs. This corresponded well with previous studies that demonstrated
that the pro-aggregatory properties of the TEML were mainly attributed to the native
collagen secretion of the SMCs [32] and is consistent with our previous work under stirred
conditions [18]. Additional synthesis and secretion of thrombogenic molecules may also
contribute to platelet activation and aggregation.
3.3. TEBVs Prevent Platelet Aggregation under Physiological Flow Conditions
The endothelial lining of the native human artery produces platelet inhibitors such
as nitric oxide (NO) and prostaglandins to prevent thrombosis. Upon vascular damage,
the loss of the antithrombotic endothelial lining, and the exposure of the prothrombotic
properties of the medial layer, triggers thrombus formation. To test whether the TEBV is
able to replicate this endothelium-dependent modulation of the haemostatic properties of
the construct under physiological flow conditions, TEBVs with differences in the integrity
of the endothelial cell layer were exposed to human platelet suspension under arterial
shear stresses. In these experiments, we used (i) a TEBV with a fully confluent endothelial
layer, (ii) a TEBV with a partially confluent endothelial layer, and (iii) a TEBV in which an
intimal injury was triggered with FeCl3, a common injury model used in murine thrombosis
models [33].
Real-time fluorescence imaging revealed that TEBVs with an intact, confluent en-
dothelial layer did not show platelet aggregation upon their surfaces over a 15 min period
of perfusion (Figure 5I (A)). In contrast, the TEBV with a partially confluent endothelial
layer exhibited limited platelet aggregation. Platelets adhered only in areas that were not
covered with endothelial cells, allowing their direct contact with the media layer. However,
not all the areas lacking endothelial coverage showed platelet aggregation, suggesting that
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the endothelial cells on the TEIL may be capable of secreting sufficient anti-thrombotic
molecules to prevent platelet aggregation (Figure 5I (B,C)). Dramatic contrast observa-
tions of platelets’ aggregation behaviours on FeCl3-lesioned TEBV samples were revealed
as shown in Figure 5I (D), in which massive platelet aggregates are attached to the con-
structs. The insert picture shows the dense morphology of the aggregated platelets, and
the low magnification image shows the overall localisation of the aggregates. The strip-like
aggregate location was larger than the lesion area (1 mm2), implying that cytokines pro-
duced by lesioned endothelial layer and exposed subendothelial proteins (collagens in our
model) could be circulated away from the lesion site, triggering aggregation away from
the lesion site. FeCl3-mediated endothelial cell injury allowed exposure of platelets to the
pro-aggregatory medial layer in the construct, providing a reliable FeCl3-triggered arterial
injury model.
Figure 5. Characterisation of tissue-engineered blood vessel (TEBV) constructs with full, partial,
and impaired intimal layer after exposure to platelets perfusion for 15 min at a shear stress of
22.2 dynes/cm2. (I) The fluorescence images of DiOC6-labelled human platelet suspension which
was perfused through a parallel flow chamber over the surface of the TEBV. (A) TEBV construct
cultured for 10 days with a confluent endothelial cell layer. (B,C) TEBV with a partial endothelial
layer coverage, 4-day culture, and (D) with impairment of the endothelial layer by FeCl3 incubation.
The green clumps over the construct surface indicate platelet aggregation and single platelet adhesion.
Higher magnification images of the platelet aggregates are shown in the inserts. (II) The aggregometer
analysis of the aggregation state of the platelet solution before and after exposure to tissue-engineered
blood vessels (TEBVs). The data represent mean ± SEM; n = 3. Significance is indicated by (*),
p ≤ 0.01.
These qualitative results correspond well with the comparison of the quantitative
aggregation state of the platelets before and after perfusion, in which FeCl3 injury could
be seen to trigger aggregation of platelets within the platelet suspension (Figure 5II).
In regards to the integrity of the endothelial layer, it can be observed that measurements of
the absorbance, before and after perfusion, do not present a significant difference in the
TEBV with a full endothelial layer. This indicates that platelet aggregation is prevented
by the presence of an intact endothelial layer. On the contrary, significant differences in
platelet aggregation were observed in FeCl3-treated TEBVs. This is consistent with platelets
producing and releasing autocrine activators to recruit platelets to the growing thrombi,
thus triggering platelet aggregation within the platelet suspension.
3.4. Ketamine Inhibited Platelet Aggregation at Arterial Shear Stress
The data above demonstrate that the TEML, and the FeCl3-treated TEBV, trigger
platelet aggregation through the exposure of the pro-aggregatory medial layer in the
endothelial denuded section of these constructs. Thus, our TEBV perfusion system can
be used in conjunction with the FeCl3 injury model, which is commonly used in murine
thrombosis models [33]. As our human TEBV model does not require the addition of
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anaesthetics to our blood samples, experiments were performed to assess if the addition
of ketamine, the most commonly used anaesthetic in murine thrombosis models, could
artificially alter the platelet aggregatory responses seen. As the TEML provides a more
pronounced aggregatory response due to the absence of an endothelial lining, we used
this system to investigate whether ketamine could impact thrombus formation by human
platelets under physiological flow conditions. DiOC6-labelled platelets were treated with
300 µM ketamine prior to perfusion over the TEML surface under arterial shear stress
(22.2 dynes/cm2). Significant platelet aggregation was found in the TEML perfused at high
shear stress without ketamine treatment (Figure 6). The platelets treated with ketamine
were found to lose their ability to adhere to the TEML surface. These results indicate
that ketamine-treated platelets (Figure 6I (B)) were less reactive than untreated platelets
(Figure 6I (A)), which showed significant aggregation on the surface. Ketamine not only
significantly inhibited platelet aggregation on the construct surface but also inhibited their
activation within the surrounding platelet suspension, as demonstrated by the aggregation
state of platelets before and after exposure to the TEML (Figure 6II). This is likely due to the
known effect of ketamine inhibiting platelet Ca2+ signalling [34,35]. This would prevent
dense granule secretion, which would in turn prevent the activation of these cells in the
perfused platelet suspension.
Figure 6. Characterisation of perfused platelet solution to the surface TEML incubated with and
without ketamine under physiological shear strain. (I) The fluorescence images of DiOC6-labelled
human platelet suspension which was perfused through a parallel flow chamber over the surface of
the TEML. Human platelet suspensions were treated with 300 µM ketamine or an equivalent volume
of its vehicle, HBS, and perfused over the TEML for 15 min using a parallel-plate flow chamber at
22.2 dynes/cm2. Images were recorded in real-time over the course of 15 min. (A) Untreated sample;
(B) Ketamine-treated sample. (T0) Beginning of perfusion; (T7) 7 min into perfusion; (T15) 15 min
into perfusion. (II) Aggregometer analysis of the aggregation state of the perfused platelet solution.
Aggregation states of platelets untreated (left) and pre-treated (right) with ketamine before and after
perfusion over TEML surface. Error bars represent SEM. Significance is indicated by (*), p ≤ 0.05.
To further confirm the inhibitory effect of ketamine on platelets, the platelets treated or
untreated with ketamine were exposed to corresponding TEMLs in cuvette holders under
continuous magnetic stirring. Representative images are shown in Figure 7.
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Figure 7. Visible and fluorescence images illustrating the state of platelet aggregation after TEML
incubation either with or without ketamine. Constructs were first incubated with 1 mM ketamine,
at 37 ◦C, for 1 h then a 15 min incubation, also at 37 ◦C, with 1 mL of washed platelets that were
pre-treated with 1 mM ketamine. Following the second incubation, platelets were washed, and
aggregates on the surface were imaged with a fluorescent microscope. Images (A–C): untreated
samples. Images (D–F): ketamine-treated samples. Results are representative of 4 experiments, n = 6.
Scale bar = 100 µm.
Fluorescent imaging of the TEML surface exposed to DiOC6-labelled platelets showed
that samples treated with ketamine had fewer platelet aggregates appearing on the TEML
surface (Figure 7D–F). The untreated samples (Figure 7A–C) displayed greater adhesion,
as well as formation of multiple platelet aggregates.
3.5. Atorvastatin Increases EPC Attachment
Atorvastatin has been reported to increase circulating numbers of EPCs [23]. To evalu-
ate whether atorvastatin also has an effect on the recruitment and attachment of perfused
EPCs, our three TE construct variants were lesioned with FeCl3, then incubated with
60 µg/mL atorvastatin for 5 h. Constructs were then perfused with EPCs for 45 min at
22.2 dynes/cm2. EPCs were perfused at a density of 1 × 104 cells/mL. After perfusion,
constructs were imaged and attached cells quantified (Figure 8).
Across all the models shown here, it was evident that atorvastatin incubation increased
the number of cells that attached to the lesioned surfaces of the constructs (Figure 8II).
We have previously demonstrated the pro aggregatory properties of the TEML, and Figure 8
suggests that atorvastatin increases these pro-aggregatory properties. The data presented
here suggest that without either the endothelial (TEML) or medial (TEIL) layers, the
response is stronger than when both layers are present, suggesting a synergistic effect
between the medial and intimal layers in terms of modulating cell recruitment. The al-
most steady state of attachment of EPCs on the TEML suggests that the FeCl3 lesion is
not the driving factor for cell attachment but rather time-dependent signalling/cytokine
production by the representative cells and the presence of atorvastatin.
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Figure 8. Characterisation of perfusion and attachment of endothelial progenitor cells on TE con-
structs with and without 60 µg/mL atorvastatin (5 h pre-incubation). (I) Representative carboxyflu-
orescein succinimidyl ester (CFSE)-labelled EPC perfusion images. For all models (TEML, TEIL,
TEBV), A is with atorvastatin, B is without atorvastatin. Green dots are EPCs. (II) The quantification
of EPC attachment. Error bars represent SEM, n = 3 for all samples. p ≤ 0.05. Significance is indicated
by (**).
4. Discussion
Being able to rapidly and effectively screen novel and pre-existing drug therapies for
the treatment of cardiovascular disease in a human model system would provide a signifi-
cant advance in our abilities to treat patients at risk of a thrombotic event. In this paper,
we demonstrate that our human TEBVs are able to effectively trigger both the activation
of thrombus formation and EPC recruitment to vascular injury under physiological flow
conditions. Through the use of this humanised experimental system, we should be able
to better determine effective drug concentrations and combinations prior to clinical trials.
Additionally, it would reduce our need to perform costly, ethically challenging preclinical
trials on animals, which require the use of anaesthetics that may significantly impact the
results of these trials. Thus, tissue engineered human blood vessel models show promise
in improving the translational potential of preclinical studies of drug delivery, drug action,
and drug discovery in pharmaceutical research.
Through developing PDMS sample holders and perfusion gaskets, we were able to
successfully modify a commercially available parallel flow chamber to incorporate our
previously described TEBV. This allowed us to examine whether these constructs are able
to support thrombus activation and EPC recruitment under physiological flow conditions.
In this study, we confirmed that, similar to static conditions, our acellular type I rat collagen
hydrogel is unable to support significant human platelet activation under physiological
flow conditions. However, our TEML constructs have been shown to produce type I and III
neo-collagen that is able to trigger significant platelet activation [18]. Here we demonstrate
that these are able to support significant platelet activation under arterial shear stresses
but not under those more typically found in large veins. This is consistent with previous
work [36,37] demonstrating that thrombus formation is regulated by shear-dependent
platelet aggregation, thus confirming that our TEBV can replicate the normal haemostatic
properties of native blood vessels. In contrast, the presence of an intact intimal layer
completely blocks the activation of human platelets perfused over the surface of the TEBV.
However, when the endothelial layer was impaired, either by incomplete coverage of
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endothelial cells (via a shortened culture period) or via FeCl3-induced injury, the TEBV
constructs were able to trigger an effective haemostatic reaction consistent with that seen
in the native artery (Figure 5). FeCl3-injured TEML also displayed platelet aggregation
under flow, an observation that was absent on uninjured constructs. Location of FeCl3
application had no impact on this observation, demonstrating that the observed effect is
due to endothelial damage caused by FeCl3 and not via the presence of FeCl3 itself [33,38].
This can be concluded as no enhancement of platelet activation and aggregation observed
upon FeCl3 treatment of the endothelial-free TEML constructs (data not shown). The data
presented here support the traditional explanation that FeCl3-induced injury results in
thrombus formation in murine arteries through endothelial denudation, facilitating platelet
activation upon the exposure of sub-endothelial collagen. These findings demonstrate
that this test model can be used to study platelet inhibition and activation in a convenient,
operator-friendly, and dynamic manner. The image analysis of the adhered platelets on the
TE constructs, and assessment of platelet aggregation in liquid phase using aggregometry,
allows the extraction of both qualitative and quantitative datasets to assess ex vivo human
thrombus formation.
This study demonstrated that ketamine exerted a strong negative effect on platelet
aggregation and activation. This corresponds well with previous in vitro and in vivo stud-
ies that have investigated the underlying mechanisms of ketamine’s inhibition of platelet
function [6]. In our experiments, we observed that ketamine almost completely inhibits
thrombus formation upon the TEML construct. It is possible that this effect is caused by
the inhibition of dense granule secretion by ketamine, as autocrine signalling molecules
released from here are known to be crucial to the recruitment of circulating platelets onto
the surface of forming thrombi [7,39]. This inhibitory effect could artefactually alter the size
and structure of thrombi seen in current animal thrombosis models, potentially leading to
an overestimation of the effectiveness of putative anti-platelet therapies. This is consistent
with previous findings that show that the use of different anaesthetics differentially impacts
the efficacy of integrin αIIbβ3 blockers in murine thrombosis models [39], thus providing
initial evidence that our model system is a potential alternative to current in vivo studies.
A more detailed side-by-side comparison examining the impact of different anaesthetics
on the thrombotic response in current in vivo models, and in the TEBV model presented
here, will be required to fully validate the model system.
These findings highlight the value of using tissue-engineered human blood vessels for
drug testing. By using human cells and eliminating the need for anaesthesia, we should
be able to accurately model the processes of haemostasis and vascular repair to improve
the translational potential of any findings. Additional advantages of our model include
a reduction in the use of animal thrombosis models, elimination of the need for costly
intravital microscopy equipment, and a lower cost of TE construct production compared to
housing mouse colonies.
We also used the TEBV to demonstrate that atorvastatin enhances recruitment and
attachment of perfused EPCs. Although previous studies have demonstrated that atorvas-
tatin increases circulating numbers of EPCs [19], there has been limited study on its ability
to modulate EPC recruitment to the damaged vascular wall, which may partly underlie the
beneficial effects of this drug in preventing acute cardiovascular events. Possible mech-
anisms by which atorvastatin might enhance EPC recruitment to the damaged TEBV is
via increased bioavailability of NO [40] or activation of matrix metalloproteinase-2 and
9 (MMP2 and MMP9) [41]. It is also possible that the SDF-1 CXCR4 axis is also involved
in recruiting EPCs to sites of vascular injury. This theory is supported by the findings
by Luo et al., 2018 [42]. They found that NO production was induced by SDF-1, which
triggers multiple signalling pathways, resulting in chemokine-induced changes of the
EPC cytoskeleton leading to enhanced cell migration [42]. The value of our models is
that various doses/concentrations of different drugs, as well as combinations of drugs,
can be tested faster than conventional models and also allows for real-time monitoring
without measures such as anaesthesia being needed. The ease of assembly also makes it
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possible to combine multiple cell types and can be adapted for any species. In comparison
to other in vitro models [43,44], our models also allow for real-time visualisation of cell
attachment due to the nature of the perfusion chamber used, containing both a top and
bottom window, as well as the open-faced nature of the models themselves.
5. Conclusions
The layer-by-layer assembly of human blood vessel models provides a convenient
and reliable research tool to investigate the interaction of blood components, such as
platelets and circulated progenitor cells, with a blood vessel. This provides a simple
method to assess the impact of a variety of drug interactions on haemostasis and vascular
repair. The parallel-plate flow chamber, plus the adjustable dimensions of the PDMS
gasket, enabled incorporation of 3D tissues into the chamber, permitting their exposure to
perfusion with blood components at different physiological shear stresses. The labelled
cells allow the monitoring of cellular activation and adhesion in real-time. The intact,
confluent intimal layer can inhibit platelet activation, whilst the partially formed intima
did not. The medial layer with newly formed collagen triggered platelet aggregation,
whilst collagen gel made from rat skin collagen type I did not. The presence of a similar
concentration of ketamine used in current in vivo thrombosis models inhibited the ability
of human platelets to adhere to the TEML surface. The tissue-engineered vessels could
also be used to demonstrate that atorvastatin is able to enhance the homing capabilities
of EPCs by improving their ability to adhere to the damaged tissue-engineered blood
vessel under flow conditions. Here we show that the combination of tissue-engineered
arterial constructs and a parallel-plate flow chamber can be used to effectively simulate the
haemostatic and vascular repair processes ex vivo. Therefore, these results indicate that this
model system is able to provide a potential alternative to in vivo testing models. This will
also permit us to test the predicted mechanisms of action of a selected anti-thrombotic
drug without the need for animal models and may be modified further to simulate other
clinical conditions.
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